| An atlas of genetic influences on osteoporosis in humans and mice JA Morris, JP Kemp, SE Youlten, L Laurent, JG Logan, RC Chai, ... Nature genetics 51 (2), 258-266, 2019 | 713 | 2019 |
| Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity CM Shipman, MJ Rogers, JF Apperley, RGG Russell, PI Croucher British journal of haematology 98 (3), 665-672, 1997 | 523 | 1997 |
| Bone Metastases R Coleman, P Croucher, A Padhani, P Clezardin, E Chow, M Fallon, ... Nature Reviews Disease Primers 6, 2020 | 511 | 2020 |
| The dormant cancer cell life cycle TG Phan, PI Croucher Nature Reviews Cancer 20 (7), 398-411, 2020 | 475 | 2020 |
| Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis JP Kemp, JA Morris, C Medina-Gomez, V Forgetta, NM Warrington, ... Nature genetics 49 (10), 1468-1475, 2017 | 468 | 2017 |
| Bone metastasis: the importance of the neighbourhood PI Croucher, MM McDonald, TJ Martin Nature Reviews Cancer 16 (6), 373-386, 2016 | 467 | 2016 |
| Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma PI Croucher, CM Shipman, J Lippitt, M Perry, K Asosingh, A Hijzen, ... Blood, The Journal of the American Society of Hematology 98 (13), 3534-3540, 2001 | 461 | 2001 |
| The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel SP Jagdev, RE Coleman, CM Shipman, A Rostami-H, PI Croucher British journal of cancer 84 (8), 1126-1134, 2001 | 461 | 2001 |
| The pharmacology of bisphosphonates and new insights into their mechanisms of action RGG Russell, MJ Rogers, JC Frith, SP Luckman, FP Coxon, HL Benford, ... Journal of Bone and Mineral Research 14 (S2), 53-65, 1999 | 394 | 1999 |
| Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche MA Lawson, MM McDonald, N Kovacic, W Hua Khoo, RL Terry, J Down, ... Nature communications 6 (1), 8983, 2015 | 374 | 2015 |
| Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells I Holen, PI Croucher, FC Hamdy, CL Eaton Cancer research 62 (6), 1619-1623, 2002 | 369 | 2002 |
| Bisphosphonates: pharmacology, mechanisms of action and clinical uses RGG Russell, PI Croucher, MJ Rogers Osteoporosis International 9, S66, 1999 | 369 | 1999 |
| Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption MM McDonald, WH Khoo, PY Ng, Y Xiao, J Zamerli, P Thatcher, W Kyaw, ... Cell 184 (5), 1330-1347. e13, 2021 | 359 | 2021 |
| Zoledronic acid treatment of 5T2MM‐bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and … PI Croucher, H De Raeve, MJ Perry, A Hijzen, CM Shipman, J Lippitt, ... Journal of Bone and Mineral Research 18 (3), 482-492, 2003 | 336 | 2003 |
| Life-course genome-wide association study meta-analysis of total body BMD and assessment of age-specific effects C Medina-Gomez, JP Kemp, K Trajanoska, J Luan, A Chesi, TS Ahluwalia, ... The American Journal of Human Genetics 102 (1), 88-102, 2018 | 327 | 2018 |
| The Bisphosphonate Incadronate (YM175) Causes Apoptosis of Human Myeloma Cells in Vitro by Inhibiting the Mevalonate Pathway CM Shipman, PI Croucher, R Graham, G Russell, MH Helfrich, MJ Rogers Cancer research 58 (23), 5294-5297, 1998 | 324 | 1998 |
| Inhibiting Dickkopf‐1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma DJ Heath, AD Chantry, CH Buckle, L Coulton, JD Shaughnessy Jr, ... Journal of Bone and Mineral Research 24 (3), 425-436, 2009 | 304 | 2009 |
| Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human … CM Shipman, PI Croucher Cancer research 63 (5), 912-916, 2003 | 289 | 2003 |
| The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network E Terpos, O Sezer, PI Croucher, R García-Sanz, M Boccadoro, ... Annals of Oncology 20 (8), 1303-1317, 2009 | 284 | 2009 |
| Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with … E Terpos, DJ Heath, A Rahemtulla, K Zervas, A Chantry, ... British journal of haematology 135 (5), 688-692, 2006 | 259 | 2006 |
